Catheter ablation of ventricular tachycardia in ischemic cardiomyopathy: Impact of concomitant amiodarone therapy on short- and long-term clinical outcomes
- PMID: 33592323
- DOI: 10.1016/j.hrthm.2021.02.010
Catheter ablation of ventricular tachycardia in ischemic cardiomyopathy: Impact of concomitant amiodarone therapy on short- and long-term clinical outcomes
Abstract
Background: Substrate catheter ablation of scar-related ventricular tachycardia (VT) is a widely accepted therapeutic option for patients with ischemic cardiomyopathy (ICM).
Objective: The purpose of this study was to investigate whether concomitant amiodarone therapy affects procedural outcomes.
Methods: A total of 134 consecutive patients (89% male; age 66 ± 10 years) with ICM undergoing catheter ablation of VT were included in the study. Patients were sorted by amiodarone therapy before ablation. In all patients, a substrate-based catheter ablation (endocardial ± epicardial) in sinus rhythm abolishing all "abnormal" electrograms within the scar was performed. The endpoint of the procedure was VT noninducibility. After the ablation procedure, all antiarrhythmic medications were discontinued. All patients had an implantable cardioverter-defibrillator, and recurrences were analyzed through the device.
Results: In 84 patients (63%), the ablation was performed on amiodarone; the remaining 50 patients (37%) were off amiodarone. Patients had comparable baseline characteristics. Mean scar size area was 143.6 ± 44.9 cm2 on amiodarone vs 139.2 ± 36.8 cm2 off amiodarone (P = .56). More radiofrequency time was necessary to achieve noninducibility in the off-amiodarone group compared to the on-amiodarone group (68.1 ± 20.1 minutes vs 51.5 ± 19.7 minutes; P <.001). In addition, due to persistent VT inducibility, more patients in the off-amiodarone group required epicardial ablation than in the on-amiodarone group (13/50 [26%] vs 5/84 [6%], respectively; P <.001). During mean follow-up of 23.9 ± 11.6 months, recurrence of any ventricular arrhythmias off antiarrhythmic drugs was 44% (37/84) in the on-amiodarone group vs 22% (11/50) in the off-amiodarone group (P = .013).
Conclusion: Albeit, VT noninducibility after substrate catheter ablation for scar related VT was achieved faster, with less radiofrequency time and less need for epicardial ablation in patients taking amiodarone, these patients had significantly higher VT recurrence at long-term follow-up when this medication was discontinued.
Keywords: Amiodarone; Antiarrhythmic drugs; Catheter ablation; Electrical storm; Ischemic cardiomyopathy; Ventricular tachycardia; Ventricular tachycardia storm.
Copyright © 2021 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
Comment in
-
Amiodarone during ventricular tachycardia ablation: A total eclipse of the heart?Heart Rhythm. 2021 Jun;18(6):894-895. doi: 10.1016/j.hrthm.2021.03.026. Epub 2021 Mar 19. Heart Rhythm. 2021. PMID: 33753276 No abstract available.
Similar articles
-
Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.Curr Cardiol Rep. 2017 Sep 13;19(11):105. doi: 10.1007/s11886-017-0924-0. Curr Cardiol Rep. 2017. PMID: 28900864 Review.
-
Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease).Circ Arrhythm Electrophysiol. 2018 Jan;11(1):e005663. doi: 10.1161/CIRCEP.117.005663. Circ Arrhythm Electrophysiol. 2018. PMID: 29305400 Clinical Trial.
-
Endocardial Scar-Homogenization With vs Without Epicardial Ablation in VT Patients With Ischemic Cardiomyopathy.JACC Clin Electrophysiol. 2022 Apr;8(4):453-461. doi: 10.1016/j.jacep.2021.12.011. Epub 2022 Feb 23. JACC Clin Electrophysiol. 2022. PMID: 35246406
-
Epicardial ventricular tachycardia in ischemic cardiomyopathy: Prevalence, electrophysiological characteristics, and long-term ablation outcomes.J Cardiovasc Electrophysiol. 2018 Nov;29(11):1530-1539. doi: 10.1111/jce.13739. Epub 2018 Oct 8. J Cardiovasc Electrophysiol. 2018. PMID: 30230120
-
Catheter Ablation for Ventricular Tachycardia in Ischaemic Versus Non-Ischaemic Cardiomyopathy: A Systematic Review and Meta-Analysis.Heart Lung Circ. 2022 Aug;31(8):1064-1074. doi: 10.1016/j.hlc.2022.02.014. Epub 2022 May 25. Heart Lung Circ. 2022. PMID: 35643798
Cited by
-
Impact of Amiodarone Therapy on the Ablation Outcome of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathy.J Clin Med. 2022 Dec 7;11(24):7265. doi: 10.3390/jcm11247265. J Clin Med. 2022. PMID: 36555882 Free PMC article.
-
Sex differences on outcomes of catheter ablation of ventricular tachycardia in patients with structural heart disease: A real-world systematic review and meta-analysis.Heart Rhythm O2. 2022 Dec 16;3(6Part B):847-856. doi: 10.1016/j.hroo.2022.09.009. eCollection 2022 Dec. Heart Rhythm O2. 2022. PMID: 36588991 Free PMC article.
-
Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives.J Clin Med. 2021 Aug 20;10(16):3696. doi: 10.3390/jcm10163696. J Clin Med. 2021. PMID: 34441994 Free PMC article. Review.
-
Ischemic cardiomyopathy: epidemiology, pathophysiology, outcomes, and therapeutic options.Heart Fail Rev. 2024 Jan;29(1):287-299. doi: 10.1007/s10741-023-10377-4. Epub 2023 Dec 16. Heart Fail Rev. 2024. PMID: 38103139 Review.
-
Prevalence and Clinical Implications of COVID-19 Myocarditis.Card Electrophysiol Clin. 2022 Mar;14(1):53-62. doi: 10.1016/j.ccep.2021.11.001. Epub 2021 Nov 9. Card Electrophysiol Clin. 2022. PMID: 35221085 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical